[go: up one dir, main page]

PE20081256A1 - Triazalopiridacina como modulador de la actividad proteina cinasa - Google Patents

Triazalopiridacina como modulador de la actividad proteina cinasa

Info

Publication number
PE20081256A1
PE20081256A1 PE2007001436A PE2007001436A PE20081256A1 PE 20081256 A1 PE20081256 A1 PE 20081256A1 PE 2007001436 A PE2007001436 A PE 2007001436A PE 2007001436 A PE2007001436 A PE 2007001436A PE 20081256 A1 PE20081256 A1 PE 20081256A1
Authority
PE
Peru
Prior art keywords
halogen
triazalopyridacine
modulator
protein kinase
kinase activity
Prior art date
Application number
PE2007001436A
Other languages
English (en)
Inventor
Christopher Ronald Smith
Pierre-Yves Bounaud
Elizabeth Anne Jefferson
Patrick S Lee
Eduardo Torres
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of PE20081256A1 publication Critical patent/PE20081256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN DERIVADO DE TRIAZALOPIRIDACINA DE FORMULA (I), DONDE A ES UN GRUPO ARILO O HETEROARILO; Q ES H, HALOGENO, AMINO, PERFLUOROALQUILO, ENTRE OTROS; T ES CH2, CH(HALOGENO), C(HALOGENO), ENTRE OTROS; X ES N O CR2; R1 Y R2 SON H, HALOGENO, NITRO, CIANO, OH, ENTRE OTROS; R28' Y R28'' SON H, HALOGENO, NITRO, CIANO, ENTRE OTROS; R35 ES UN ENLACE, H, HALOGENO, NITRO, OH, ENTRE OTROS; z ES UN ENTERO DE 0 A 3. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE LA TIROSINA CINASAS, PARTICULARMENTE, MET Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2007001436A 2006-10-23 2007-10-23 Triazalopiridacina como modulador de la actividad proteina cinasa PE20081256A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
PE20081256A1 true PE20081256A1 (es) 2008-10-13

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001436A PE20081256A1 (es) 2006-10-23 2007-10-23 Triazalopiridacina como modulador de la actividad proteina cinasa

Country Status (16)

Country Link
US (1) US8071581B2 (es)
EP (1) EP2081937B1 (es)
JP (1) JP2010507577A (es)
KR (1) KR101083177B1 (es)
AU (1) AU2007309237B2 (es)
BR (1) BRPI0717317A2 (es)
CA (1) CA2667453A1 (es)
DK (1) DK2081937T3 (es)
EA (1) EA016527B1 (es)
ES (1) ES2393132T3 (es)
MX (1) MX2009004060A (es)
PE (1) PE20081256A1 (es)
PL (1) PL2081937T3 (es)
PT (1) PT2081937E (es)
TW (1) TW200833692A (es)
WO (1) WO2008051805A2 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014KN02423A (es) 2006-04-07 2015-05-01 Vertex Pharma
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
DK2497470T3 (en) 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
CN103936743B (zh) * 2008-05-21 2018-04-24 因西特控股公司 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
US8912330B2 (en) 2008-12-12 2014-12-16 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
EP2396333B1 (en) * 2009-02-10 2013-07-03 AstraZeneca AB Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer
EP2406264A4 (en) 2009-03-09 2012-08-08 Univ California SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINE AND GABAA RECEPTORS
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
WO2011079804A1 (en) * 2009-12-31 2011-07-07 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) * 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
EA201690998A1 (ru) 2010-05-17 2017-01-30 Инкозен Терапьютикс Пвт. Лтд. НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CA2800664C (en) 2010-06-01 2019-09-24 Angion Biomedica Corp. Benzothiazole cytochrome p450 inhibitors and therapeutic uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN104024259B (zh) 2011-09-27 2017-09-26 基恩菲特公司 作为Rev‑Erb激动剂的6‑取代的三唑并哒嗪类衍生物
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
EA026412B1 (ru) 2012-03-30 2017-04-28 Ризен Фармасьютикалз Са НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ c-MET ПРОТЕИНКИНАЗ
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
EP2909193B1 (en) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenyl linked quinolinyl modulators of ror-gamma-t
HK1213250A1 (zh) 2012-10-16 2016-06-30 Janssen Pharmaceutica, N.V. RORγT的雜芳基連接的喹啉基調節劑
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
US9846345B2 (en) 2013-02-28 2017-12-19 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
AR095365A1 (es) 2013-03-13 2015-10-14 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina
SG11201506687RA (en) * 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
US20140303121A1 (en) * 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
EP3424534B1 (en) 2014-04-15 2021-06-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
ES2857076T3 (es) * 2015-04-13 2021-09-28 Five Prime Therapeutics Inc Terapia de combinación para cáncer
KR102665765B1 (ko) 2015-07-20 2024-05-10 젠자임 코포레이션 콜로니 자극 인자-1 수용체(csf-1r) 저해제
WO2019075243A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. SOLID FORMS OF A COMPOUND FOR MODULATING KINASES
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
WO2003014649A1 (en) * 2001-08-10 2003-02-20 Yokohama Tlo Company Ltd. Heat transfer device
PT1966214T (pt) * 2005-12-21 2017-02-03 Janssen Pharmaceutica Nv Triazolpiridazinas como moduladores de tirosina quinase
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Also Published As

Publication number Publication date
JP2010507577A (ja) 2010-03-11
TW200833692A (en) 2008-08-16
PT2081937E (pt) 2012-10-15
EP2081937A2 (en) 2009-07-29
ES2393132T3 (es) 2012-12-18
AU2007309237A1 (en) 2008-05-02
US8071581B2 (en) 2011-12-06
WO2008051805A2 (en) 2008-05-02
EP2081937B1 (en) 2012-09-12
AU2007309237B2 (en) 2012-03-22
MX2009004060A (es) 2009-06-19
DK2081937T3 (da) 2012-10-01
EA016527B1 (ru) 2012-05-30
EA200970402A1 (ru) 2009-10-30
WO2008051805A3 (en) 2008-07-10
CA2667453A1 (en) 2008-05-02
US20100120739A1 (en) 2010-05-13
BRPI0717317A2 (pt) 2013-10-22
KR20090069303A (ko) 2009-06-30
PL2081937T3 (pl) 2013-01-31
KR101083177B1 (ko) 2011-11-11

Similar Documents

Publication Publication Date Title
PE20081256A1 (es) Triazalopiridacina como modulador de la actividad proteina cinasa
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
EA200601785A1 (ru) Соединения и способы лечения дислипидемии
EA200700120A1 (ru) Соединения и способы лечения дислипидемии
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
PE20090229A1 (es) DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
BRPI0513310A (pt) análogos de tetrapeptìdeo
EA200971077A1 (ru) Гетероциклические модуляторы киназы
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
ATE433447T1 (de) Pyrimiidinverbindungen
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
CL2007003756A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
PE20070602A1 (es) Compuestos de carboxiamina como moduladores de histona desacetilasa
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ATE461188T1 (de) Verstärker von glutamat-rezeptoren
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
UY29656A1 (es) Grupos de compuestos de amino benzoilos heterociclilos, composiciones farmacéuticas que los contienen, procesos de prepación y aplicaciones
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed